Your activity: 2 p.v.

Our approach to lipid screening in children and adolescents

Our approach to lipid screening in children and adolescents
CVD: cardiovascular disease; CoA: coarctation of the aorta; AS: aortic stenosis; TGA: transposition of the great arteries; HCM: hypertrophic cardiomyopathy; SLE: systemic lupus erythematosus; JIA: juvenile idiopathic arthritis; HDL-C: high-density lipoprotein cholesterol; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol.
* Initial screening can be performed with a fasting or nonfasting lipid profile (with the latter, non-HDL-C is calculated based on the directly measured TC and HDL-C levels). Confirmatory testing with a fasting lipid profile should be performed if adverse levels are noted on initial screen (ie, TC ≥200 mg/dL, HDL-C <40 mg/dL, LDL-C ≥130 mg/dL, or non-HDL ≥145 mg/dL). For additional details, refer to the UpToDate topic on screening and diagnosis of dyslipidemia in children.
¶ These are general suggestions for the timing and interval of screening; they should be tailored to the child's specific risk profile. For example, for a child with a single risk factor that does not place him/her into the high-risk category (eg, nonsevere obesity or smoke exposure without any additional risk factors), it is reasonable to begin screening later and repeat it less frequently. By contrast, for a child with risk factors that place him/her in the high-risk category (eg, Kawasaki disease with known coronary artery aneurysm), it is reasonable to perform lipid screening earlier and more frequently.
Δ Family history of premature CVD is generally defined as heart attack, treated angina, interventions for coronary artery disease, sudden cardiac death, or ischemic stroke in a male parent or sibling before 55 years of age or a female parent or sibling before 65 years of age.
Adapted from:
  1. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics 2011; 128 Suppl 5:S213.
  2. de Ferranti SD, Steinberger J, Ameduri R, et al. Cardiovascular risk reduction in high-risk pediatric patients: A scientific statement from the American Heart Association. Circulation 2019; 139:e603.
Graphic 105367 Version 8.0